Lantheus Competitors

Myriad Genetics (NASDAQ:MYGN) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.

Profitability

This table compares Myriad Genetics and Lantheus' net margins, return on equity and return on assets.

Risk and Volatility

Myriad Genetics has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, Lantheus has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Myriad Genetics and Lantheus, as reported by MarketBeat.

Myriad Genetics currently has a consensus target price of $13.25, indicating a potential downside of 51.77%. Lantheus has a consensus target price of $21.50, indicating a potential upside of 39.79%. Given Lantheus' stronger consensus rating and higher possible upside, analysts clearly believe Lantheus is more favorable than Myriad Genetics.

Valuation & Earnings

This table compares Myriad Genetics and Lantheus' revenue, earnings per share (EPS) and valuation.

Lantheus has lower revenue, but higher earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

96.7% of Myriad Genetics shares are owned by institutional investors. Comparatively, 85.0% of Lantheus shares are owned by institutional investors. 2.8% of Myriad Genetics shares are owned by company insiders. Comparatively, 2.1% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Lantheus beats Myriad Genetics on 9 of the 14 factors compared between the two stocks.

Heska (NASDAQ:HSKA) and Lantheus (NASDAQ:LNTH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.

Valuation and Earnings

This table compares Heska and Lantheus' top-line revenue, earnings per share (EPS) and valuation.

Lantheus has higher revenue and earnings than Heska. Lantheus is trading at a lower price-to-earnings ratio than Heska, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Heska has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Lantheus has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500.

Profitability

This table compares Heska and Lantheus' net margins, return on equity and return on assets.

Institutional and Insider Ownership

96.1% of Heska shares are held by institutional investors. Comparatively, 85.0% of Lantheus shares are held by institutional investors. 11.7% of Heska shares are held by insiders. Comparatively, 2.1% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for Heska and Lantheus, as provided by MarketBeat.com.

Heska presently has a consensus price target of $131.1250, indicating a potential downside of 21.37%. Lantheus has a consensus price target of $21.50, indicating a potential upside of 39.79%. Given Lantheus' higher possible upside, analysts clearly believe Lantheus is more favorable than Heska.

Summary

Lantheus beats Heska on 8 of the 14 factors compared between the two stocks.

Lantheus (NASDAQ:LNTH) and Riot Blockchain (NASDAQ:RIOT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk.

Institutional and Insider Ownership

85.0% of Lantheus shares are owned by institutional investors. Comparatively, 9.0% of Riot Blockchain shares are owned by institutional investors. 2.1% of Lantheus shares are owned by insiders. Comparatively, 3.5% of Riot Blockchain shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Lantheus and Riot Blockchain's net margins, return on equity and return on assets.

Risk and Volatility

Lantheus has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, Riot Blockchain has a beta of 4.56, indicating that its share price is 356% more volatile than the S&P 500.

Valuation & Earnings

This table compares Lantheus and Riot Blockchain's gross revenue, earnings per share and valuation.

Lantheus has higher revenue and earnings than Riot Blockchain. Riot Blockchain is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Lantheus and Riot Blockchain, as provided by MarketBeat.

Lantheus presently has a consensus price target of $21.50, indicating a potential upside of 39.79%. Riot Blockchain has a consensus price target of $7.50, indicating a potential downside of 66.34%. Given Lantheus' higher probable upside, equities analysts clearly believe Lantheus is more favorable than Riot Blockchain.

Summary

Lantheus beats Riot Blockchain on 10 of the 14 factors compared between the two stocks.

Meridian Bioscience (NASDAQ:VIVO) and Lantheus (NASDAQ:LNTH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Institutional & Insider Ownership

88.3% of Meridian Bioscience shares are owned by institutional investors. Comparatively, 85.0% of Lantheus shares are owned by institutional investors. 2.0% of Meridian Bioscience shares are owned by company insiders. Comparatively, 2.1% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Meridian Bioscience and Lantheus' net margins, return on equity and return on assets.

Risk and Volatility

Meridian Bioscience has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, Lantheus has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500.

Valuation & Earnings

This table compares Meridian Bioscience and Lantheus' revenue, earnings per share and valuation.

Meridian Bioscience has higher earnings, but lower revenue than Lantheus. Lantheus is trading at a lower price-to-earnings ratio than Meridian Bioscience, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Meridian Bioscience and Lantheus, as reported by MarketBeat.

Meridian Bioscience presently has a consensus target price of $28.00, indicating a potential upside of 22.81%. Lantheus has a consensus target price of $21.50, indicating a potential upside of 39.79%. Given Lantheus' higher probable upside, analysts plainly believe Lantheus is more favorable than Meridian Bioscience.

Summary

Meridian Bioscience beats Lantheus on 8 of the 14 factors compared between the two stocks.

Celldex Therapeutics (NASDAQ:CLDX) and Lantheus (NASDAQ:LNTH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of current ratings for Celldex Therapeutics and Lantheus, as reported by MarketBeat.

Celldex Therapeutics presently has a consensus target price of $21.50, indicating a potential upside of 14.85%. Lantheus has a consensus target price of $21.50, indicating a potential upside of 39.79%. Given Lantheus' higher probable upside, analysts plainly believe Lantheus is more favorable than Celldex Therapeutics.

Risk and Volatility

Celldex Therapeutics has a beta of 2.96, suggesting that its stock price is 196% more volatile than the S&P 500. Comparatively, Lantheus has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500.

Profitability

This table compares Celldex Therapeutics and Lantheus' net margins, return on equity and return on assets.

Institutional & Insider Ownership

80.2% of Celldex Therapeutics shares are owned by institutional investors. Comparatively, 85.0% of Lantheus shares are owned by institutional investors. 2.4% of Celldex Therapeutics shares are owned by company insiders. Comparatively, 2.1% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Celldex Therapeutics and Lantheus' revenue, earnings per share and valuation.

Lantheus has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Summary

Lantheus beats Celldex Therapeutics on 9 of the 14 factors compared between the two stocks.

Lantheus (NASDAQ:LNTH) and Aspira Women's Health (NASDAQ:AWH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Earnings and Valuation

This table compares Lantheus and Aspira Women's Health's top-line revenue, earnings per share and valuation.

Lantheus has higher revenue and earnings than Aspira Women's Health. Aspira Women's Health is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Lantheus has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Aspira Women's Health has a beta of 3.28, suggesting that its share price is 228% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Lantheus and Aspira Women's Health, as reported by MarketBeat.com.

Lantheus currently has a consensus target price of $21.50, suggesting a potential upside of 39.79%. Given Lantheus' higher probable upside, research analysts clearly believe Lantheus is more favorable than Aspira Women's Health.

Profitability

This table compares Lantheus and Aspira Women's Health's net margins, return on equity and return on assets.

Institutional and Insider Ownership

85.0% of Lantheus shares are held by institutional investors. Comparatively, 24.6% of Aspira Women's Health shares are held by institutional investors. 2.1% of Lantheus shares are held by company insiders. Comparatively, 4.7% of Aspira Women's Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Lantheus beats Aspira Women's Health on 9 of the 12 factors compared between the two stocks.